Last reviewed · How we verify
Booster vaccination
A booster vaccination reinforces and enhances the immune response by stimulating memory B and T cells to increase antibody production and cellular immunity against a previously encountered pathogen.
A booster vaccination reinforces and enhances the immune response by stimulating memory B and T cells to increase antibody production and cellular immunity against a previously encountered pathogen. Used for Booster vaccination for infectious disease prevention (specific pathogen dependent on formulation).
At a glance
| Generic name | Booster vaccination |
|---|---|
| Sponsor | Institute of Tropical Medicine, Belgium |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Booster vaccinations work by re-exposing the immune system to antigen(s) from a pathogen, triggering rapid proliferation of existing memory immune cells and generating higher-affinity antibodies and stronger T-cell responses than the primary vaccination series alone. This restores or maintains protective immunity levels that may have waned over time, particularly important for diseases where immunity naturally declines or where sustained protection is critical for public health.
Approved indications
- Booster vaccination for infectious disease prevention (specific pathogen dependent on formulation)
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Myalgia
- Headache
Key clinical trials
- A Self-management Program to Prevent Falls in People With Multiple Sclerosis (NA)
- Rwanda Digital Dashboard Hybrid Type 3 Implementation Study (NA)
- Engage Coaching (R33 Phase) (NA)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Testing the SurVaxM Vaccine for Lung Cancer Prevention (PHASE2)
- Improving Care Through Azithromycin Research for Infants in Africa (PHASE3)
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes (PHASE1)
- Early-Stage Partner in Care Living Alone Plus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Booster vaccination CI brief — competitive landscape report
- Booster vaccination updates RSS · CI watch RSS
- Institute of Tropical Medicine, Belgium portfolio CI